Hailshadow / iStockphoto.com
14 June 2018Americas
PTAB rejects IPR challenges to Gilead patents
The Patent Trial and Appeal Board (PTAB) has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Asia
20 June 2018 Humanitarian organisation Médecins Sans Frontières has challenged a patent owned by Gilead in China.
Americas
24 July 2018 The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.
Biotechnology
20 July 2020 Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.
Editor's picks
Editor's picks
Asia
20 June 2018 Humanitarian organisation Médecins Sans Frontières has challenged a patent owned by Gilead in China.
Americas
24 July 2018 The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.
Biotechnology
20 July 2020 Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.
Asia
20 June 2018 Humanitarian organisation Médecins Sans Frontières has challenged a patent owned by Gilead in China.
Americas
24 July 2018 The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.
Biotechnology
20 July 2020 Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.